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2987Preamble and Transition to ACC/AHA
Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC)
and the American Heart Association (AHA) are to prevent
cardiovascular diseases (CVD); improve the management of
people who have these diseases through professional edu-
cation and research; and develop guidelines, standards, and
policies that promote optimal patient care and cardiovascular
health. Toward these objectives, the ACC and AHA have
collaborated with the National Heart, Lung, and Blood
Institute (NHLBI) and stakeholder and professional orga-
nizations to develop clinical practice guidelines for assess-
ment of cardiovascular risk, lifestyle modiﬁcations to reduce
cardiovascular risk, management of blood cholesterol in
adults, andmanagement of overweight and obesity in adults.
In 2008, the NHLBI initiated these guidelines by
sponsoring rigorous systematic evidence reviews for each
topic by expert panels convened to develop critical ques-
tions (CQs), interpret the evidence, and craft recommen-
dations. In response to the 2011 report from the Institute
of Medicine on the development of trustworthy clinical
guidelines (1), the NHLBI Advisory Council recom-
mended that the NHLBI focus speciﬁcally on reviewing
the highest-quality evidence and partner with other orga-
nizations to develop recommendations (2,3). Accordingly,
in June 2013 the NHLBI initiated collaboration with
the ACC and AHA to work with other organizations to
complete and publish the 4 guidelines noted above and
make them available to the widest possible constituency.
Recognizing that the Expert Panels/Work Groups did
not consider evidence beyond 2011 (except as speciﬁed in
the methodology), the ACC, AHA, and collaborating
societies plan to begin updating these guidelines starting
in 2014.
The joint ACC/AHA Task Force on Practice Guide-
lines (Task Force) appointed a subcommittee to shepherd
this transition, communicate the rationale and expecta-
tions to the writing panels and partnering organizations,
and expeditiously publish the documents. The ACC/
AHA and partner organizations recruited a limited
number of expert reviewers for ﬁduciary examination of
content, recognizing that each document had undergone
extensive peer review by representatives of the NHLBI
Advisory Council, key federal agencies, and scientiﬁc ex-
perts. Each writing panel responded to comments from
these reviewers. Clariﬁcations were incorporated where
appropriate, but there were no substantive changes because
the bulk of the content was undisputed.
Although the Task Force led the ﬁnal development of
these prevention guidelines, they differ from other ACC/
AHA guidelines. First, as opposed to an extensive com-
pendium of clinical information, these documents are
signiﬁcantly more limited in scope and focus on selected
CQs on each topic based on the highest-quality evidenceavailable. Recommendations were derived from random-
ized trials, meta-analyses, and observational studies evalu-
ated for quality and were not formulated when sufﬁcient
evidence was not available. Second, the text accompanying
each recommendation is succinct, summarizing the evi-
dence for each question. The Full Panel/Work Group
Reports include more detailed information about the evi-
dence statements (ESs) that serve as the basis for recom-
mendations. Third, the format of the recommendations
differs from other ACC/AHA guidelines. Each recom-
mendation has been mapped from the NHLBI grading
format to the ACC/AHA Classiﬁcation of Recommen-
dation/Level of Evidence (COR/LOE) construct (Table 1)
and is expressed in both formats. Because of the inherent
differences in grading systems and the clinical questions
driving the recommendations, alignment between the
NHLBI and ACC/AHA formats is in some cases
imperfect. Explanations of these variations are noted in the
recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by
the writing panels to manage relationships of authors with
industry and other entities (RWI) are outlined in the
methods section of each panel report. These policies were
in effect when this effort began in 2008 and throughout
the writing process and voting on recommendations, until
the process was transferred to ACC/AHA in 2013. In the
interest of transparency, the ACC/AHA requested that
panel authors resubmit RWI disclosures as of July 2013.
Relationships relevant to this guideline are disclosed in
Appendix 1. None of the ACC/AHA expert reviewers had
relevant RWI (Appendix 2). See Appendix 3 for a list of
abbreviations used in this guideline.
Systematic evidence reports and accompanying summary
tables were developed by the expert panels and NHLBI.
The guideline was reviewed by the ACC/AHA Task Force
and approved by the ACC Board of Trustees, the AHA
Science Advisory and Coordinating Committee, and
The Obesity Society. In addition, ACC/AHA sought
endorsement from other stakeholders, including profes-
sional organizations. It is the hope of the writing panels,
stakeholders, professional organizations, NHLBI, and
Task Force that the guidelines will garner the widest
possible readership for the beneﬁt of patients, providers,
and the public health.
These guidelines are meant to deﬁne practices that
meet the needs of patients in most circumstances and
are not a replacement for clinical judgment. The ulti-
mate decision about care of a particular patient must be
made by the healthcare provider and patient in light of
the circumstances presented by that patient. As a result,
situations might arise in which deviations from these
guidelines may be appropriate. These considerations
notwithstanding, in caring for most patients, clinicians
can employ the recommendations conﬁdently to reduce
the risks of atherosclerotic CVD events.
Table 1. Applying Classiﬁcation of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
failure, and prior aspirin use.
yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the
treatments or strategies being evaluated.
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recommendation grading methodology.
1. Introduction/Scope of Guideline
More than 78 million adults in the United States were
obese in 2009 and 2010 (4). Obesity raises the risk of
morbidity from hypertension, dyslipidemia, type 2 diabetes
mellitus (diabetes), coronary heart disease (CHD), stroke,
gallbladder disease, osteoarthritis, sleep apnea and respi-
ratory problems, and some cancers. Obesity is also asso-
ciated with increased risk of all-cause and CVD mortality.
The biomedical, psychosocial, and economic consequences
of obesity have substantial implications for the health and
well-being of the U.S. population.According to the 1998 “Clinical Guidelines on the
Identiﬁcation, Evaluation, and Treatment of Overweight
and Obesity in AdultsdThe Evidence Report” (5), over-
weight is deﬁned as a body mass index (BMI) of 25 kg/m2
to 29.9 kg/m2 and obesity as a BMI of 30 kg/m2.
Current estimates are that 69% of adults are either over-
weight or obese, with approximately 35% obese (6). These
latest data from the National Health and Nutrition Exam-
ination Surveys indicate that for both men and women,
obesity estimates for 2009 and 2010 did not differ signiﬁ-
cantly from estimates for 2003 to 2008 and that increases in
the prevalence rates of obesity appear to be slowing down
or leveling off (6). Nevertheless, overweight and obesity
continue to be highly prevalent, especially in some racial and
ethnic minority groups, as well as in those with lower
Table 2. NHLBI Grading of the Strength of
Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net beneﬁty
is substantial.
B Moderate recommendation
There is moderate certainty based on evidence that the net beneﬁt is
moderate to substantial, or there is high certainty that the net
beneﬁt is moderate.
C Weak recommendation
There is at least moderate certainty based on evidence that there is a
small net beneﬁt.
D Recommendation against
There is at least moderate certainty based on evidence that
there is no net beneﬁt or that risks/harms outweigh beneﬁts.
E Expert opinion (“There is insufﬁcient evidence or evidence is
unclear or conﬂicting, but this is what the Work Group
recommends.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence,
unclear evidence, or conﬂicting evidence, but the Work Group
thought it was important to provide clinical guidance and
make a recommendation. Further research is recommended
in this area.
N No recommendation for or against (“There is insufﬁcient evidence or
evidence is unclear or conﬂicting.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence, unclear
evidence, or conﬂicting evidence, and the Work Group thought
no recommendation should be made. Further research is
recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned with the quality
of the evidence; however, under some circumstances, there may be valid reasons for making
recommendations that are not closely aligned with the quality of the evidence (e.g., strong
recommendation when the evidence quality is moderate, such as smoking cessation to reduce
CVD risk or ordering an ECG as part of the initial diagnostic work-up for a patient presenting with
possible MI). Those situations should be limited and the rationale explained clearly by the Work
Group.
yNet beneﬁt is deﬁned as beneﬁts minus risks/harms of the service/intervention.
CVD indicates cardiovascular disease; ECG, electrocardiogram; MI, myocardial infarction; and
NHLBI, National Heart, Lung, and Blood Institute.
Table 3. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
 Well-designed, well-executedy RCT that adequately
represent populations to which the results are applied
and directly assess effects on health outcomes.
 Meta-analyses of such studies.
Highly certain about the estimate of effect. Further
research is unlikely to change our conﬁdence in the
estimate of effect.
High
 RCT with minor limitationsz affecting conﬁdence in,
or applicability of, the results.
 Well-designed, well-executed nonrandomized controlled
studiesx and well-designed, well-executed observational
studiesk.
 Meta-analyses of such studies.
Moderately certain about the estimate of effect. Further
research may have an impact on our conﬁdence in the
estimate of effect and may change the estimate.
Moderate
 RCT with major limitations.
 Nonrandomized controlled studies and observational
studies with major limitations affecting conﬁdence in,
or applicability of, the results.
 Uncontrolled clinical observations without an appropriate
comparison group (e.g., case series, case reports).
 Physiological studies in humans.
 Meta-analyses of such studies.
Low certainty about the estimate of effect. Further
research is likely to have an impact on our conﬁdence
in the estimate of effect and is likely to change the estimate.
Low
*In some cases, other evidence, such as large all-or-none case series (e.g., jumping from air-
planes or tall structures), can represent high- or moderate-quality evidence. In such cases, the
rationale for the evidence rating exception should be explained by the Work Group and clearly
justiﬁed.
y“Well-designed, well-executed” refers to studies that directly address the question; use
adequate randomization, blinding, and allocation concealment; are adequately powered; use
intention-to-treat analyses; and have high follow-up rates.
zLimitations include concerns with the design and execution of a study that result in decreased
conﬁdence in the true estimate of the effect. Examples of such limitations include but are not
limited to: inadequate randomization, lack of blinding of study participants or outcome asses-
sors, inadequate power, outcomes of interest that are not prespeciﬁed for the primary out-
comes, low follow-up rates, and ﬁndings based on subgroup analyses. Whether the limitations
are considered minor or major is based on the number and severity of ﬂaws in design or
execution. Rules for determining whether the limitations are considered minor or major and how
they will affect rating of the individual studies will be developed collaboratively with the meth-
odology team.
xNonrandomized controlled studies refer to intervention studies where assignment to inter-
vention and comparison groups is not random (e.g., quasi-experimental study design).
kObservational studies include prospective and retrospective cohort, case-control, and cross-
sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, randomized controlled trial.
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2989incomes and less education. Overweight and obesity are
major contributors to chronic diseases in the United States
and present a major public health challenge. Compared
with normal-weight individuals, obese patients incur 46%
higher inpatient costs, 27% more physician visits and
outpatient costs, and 80% higher spending on prescription
drugs (7). The medical care costs of obesity in the United
States are staggering. In 2008 dollars, these costs totaled
about $147 billion (7).
The Expert Panel was ﬁrst convened in September 2008
by the NHLBI in cooperation with the National Institute
of Diabetes and Digestive and Kidney Diseases to update
the 1998 Clinical Guidelines Report (5). The Expert Panel
considered new evidence related to key issues on over-
weight and obesity evaluation and treatment, particularly in
individuals with other risk factors for CVD and diabetes.
The key issues identiﬁed included the appropriateness of
the current BMI and waist circumference cutpoints that
are used for determining risk in overweight and obese
adults across diverse populations; the impact of weight losson risk factors for CVD and type 2 diabetes, as well as
CVD morbidity and mortality; optimal behavioral, dietary
intervention, and other lifestyle treatment approaches for
weight loss and weight loss maintenance; and beneﬁts and
risks of various bariatric surgical procedures. The Expert
Panel’s ultimate goal was to systematically develop ESs and
recommendations for 5 CQs to assist clinicians in primary
care. The recommendations are based on evidence from a
rigorous systematic review and synthesis of recently pub-
lished medical literature.
This guideline is based on the Full Panel Report, which
is provided as an online-only data supplement to the
guideline. The Full Panel Report contains background and
additional material related to content, methodology, evi-
dence synthesis, rationale, and references and is supported
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2990by the NHLBI Systematic Evidence Review, which can be
found at http://www.nhlbi.nih.gov/guidelines/obesity/ser/.
Refer to the “2013 ACC/AHA Guideline on the Treat-
ment of Blood Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adults,” “2013 AHA/ACC
Guideline on Lifestyle Management to Reduce Cardio-
vascular Risk,” and “2013 ACC/AHA Guideline on the
Assessment of Cardiovascular Risk” (8–10) for topics
outside the scope of the 2013 AHA/ACC/TOS Obesity
Guideline.
1.1. Rationale for Updating Obesity
Clinical Guidelines
The NHLBI, in cooperation with the National Institute of
Diabetes and Digestive and Kidney Diseases, released the
1998 “Clinical Guidelines on the Identiﬁcation, Evalua-
tion, and Treatment of Overweight and Obesity in
AdultsdThe Evidence Report” (11) as a systematic review
of the published scientiﬁc literature found in MEDLINE
from January 1980 to September 1997 on important topics
reviewed by the Expert Panel. The published literature was
evaluated to determine appropriate treatment strategies
that would constitute evidence-based clinical guidelines on
overweight and obesity. The San Antonio Cochrane
Center assisted in literature abstraction and in organizing
the data into evidence tables, and a methodology consul-
tant worked with the Expert Panel to develop ESs and
recommendations.
In 2005, the NHLBI initiated the process to update the
overweight/obesity guidelines and convened stakeholder
groups to provide input on what should be the next-
generation guideline development process. The resulting
recommendations were used to design the process. To
continually improve the quality and impact of the guide-
lines, the process was updated to assure rigor and minimize
bias through the use of strict, evidence-based methodolo-
gies to guide the development of ESs and recommenda-
tions based on a systematic review of the biomedical
literature for a speciﬁc period of time.
1.2. CQ-Based Approach
The Expert Panel began its deliberations by developing 23
possible CQs, and after considerable discussion, narrowed
the possibilities to 5 targeted CQs. Questions were chosen
to aid primary care practitioners (PCPs) and providers who
frequently work with obese patients to identify patients at
health risk of weight-related comorbidities and to update
them on the beneﬁts and risks of weight loss achieved by
various approaches. Examples of CQs that were not
included for this review included consideration of genetics
of obesity, binge-eating disorders, pharmacotherapy, and
cost-effectiveness of interventions to manage obesity. For
each of the chosen CQs, Expert Panel members reviewed
the ﬁnal list of included and excluded articles, along with
the quality ratings, and had the opportunity to raise ques-
tions and appeal the ratings to the methodology team. Theteam then reexamined these articles and presented their
rationale for either keeping or changing the quality rating of
the articles. Expert Panel members also played a key role in
examining the evidence tables and summary tables to be
certain the data from each article were accurately displayed.
The body of the present report is organized by CQ and
the following information is included for each CQ:
 The rationale for its selection is provided, and
methods are described.
 The body of evidence is summarized, and ESs are
presented, which include a rating for quality and a
supportive narrative summary.
 Recommendations and their strength are accompa-
nied by a narrative summary of how the recom-
mendation was derived from the evidence and a
discussion of issues considered by the Expert Panel in
formulating the recommendation.
CQ1 and CQ2 were chosen to help providers determine
the appropriate criteria to guide a weight loss recommen-
dation. CQ1 addresses the expected health beneﬁts of
weight loss as a function of the amount and duration of
weight loss. CQ2 addresses the health risks of overweight
and obesity and seeks to determine if the current waist
circumference cutpoints and the widely accepted BMI
cutpoints deﬁning persons as overweight (BMI 25–29.9
kg/m2) and obese (BMI 30 kg/m2) are appropriate for
population subgroups. Because patients are interested in
popular diets that are promoted for weight loss and see the
PCP as an authoritative source of information, CQ3 asks
which dietary intervention strategies are effective for
weight loss efforts. CQ4 seeks to determine the efﬁcacy
and effectiveness of a comprehensive lifestyle approach
(diet, physical activity, and behavior therapy) to achieve
and maintain weight loss. CQ5 seeks to determine the
efﬁcacy and safety of bariatric surgical procedures,
including beneﬁts and risks. CQ5 also seeks to determine
patient and procedural factors that may help guide
decisions to enhance the likelihood of maximum beneﬁt
from surgery for obesity and related conditions.
1.3. Organization of the Panel
In 2007, the NHLBI sought nominations for panel
membership that would ensure adequate representation of
key specialties and appropriate expertise. The NHLBI staff
reviewed the nominees and selected potential chairs and
co-chairs for the panels. A Guidelines Executive Com-
mittee was formed, consisting of the chairs from each of
the 3 panels (obesity, high blood pressure [BP], and high
blood cholesterol) and 3 cross-cutting working groups
(lifestyle, risk assessment, and implementation). This
committee worked with the NHLBI to select panel
members from the list of nominees.
The Obesity Expert Panel comprised 15 members and
3 ex-ofﬁcio members, including individuals with speciﬁc
expertise in psychology, nutrition, physical activity,
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2991bariatric surgery, epidemiology, internal medicine, and
other clinical specialties. The full Obesity Expert Panel
met 23 times throughout the years (5 times face-to-face
and 18 times via Webinar). Expert Panel chairs asked all
members to disclose any conﬂicts of interest to the full
Expert Panel in advance of the deliberations; members
with conﬂicts were asked to recuse themselves from voting
on any aspect of the guideline for which a conﬂict might
exist. Each of the 5 CQs had working groups consisting
of a leader and various Expert Panel members who met
via conference calls to discuss all aspects of the CQ; to
review the list of included and excluded articles along
with the quality ratings; to review the evidence tables
and summary tables; and to develop spreadsheets, ESs,
resulting recommendations, and research/evidence gaps.
Expert Panel members had the opportunity to raise
questions about the included and excluded articles, submit
additional articles that were not identiﬁed in the original
search, appeal the quality ratings on articles, and question
articles that were excluded. Each working group presented
their ﬁndings to the full Expert Panel for all ﬁnal decisions
on ESs and recommendations, including the strength of
the evidence.
The evidence-based process followed most of the stan-
dards from the Institute of Medicine’s report, Clinical
Practice Guidelines We Can Trust (1). The process had sup-
port from a methodology contractor and a systematic re-
view and general support contractor and included the
following steps:
 Constructed CQs relevant to clinical practice.
 Identiﬁed (a priori) inclusion/exclusion (I/E) criteria
for each CQ.
 Developed a literature search strategy, based on I/E
criteria, for each CQ.
 Executed a systematic electronic search of the pub-
lished literature from relevant bibliographic databases
for each CQ. The date range for the overall literature
search was from January 1998 to December 2009.
Because CQ1 and CQ2 used systematic reviews and
meta-analyses, the literature search included those
published from January 2000 to October 2011. CQ3
and CQ4 added major randomized controlled trials
(RCTs) published after 2009 with >100 people per
treatment arm. CQ5 added some major studies
published after 2009 that met the I/E criteria.
 Screened, by 2 independent reviewers, thousands of
abstracts and full-text articles returned from the
search to identify relevant original articles, systematic
reviews, and meta-analyses. Rigorous validation
procedures were applied to ensure that the selected
articles met the pre-established detailed I/E criteria
before being included in the ﬁnal review results.
 Determined, by 2 independent raters on the meth-
odology team, the quality of each included study
(good, fair, and poor). Abstracted relevant information from the included
studies into an electronic central repository database
using common templates and types of data elements.
 Constructed detailed evidence tables, which orga-
nized the data from the abstraction database.
 Analyzed the evidence tables and constructed sum-
mary tables, which display the evidence in a manage-
able format to answer speciﬁc parts of each CQ.
 Used summary tables to develop ESs for each CQ.
The quality of evidence for each ES was graded as
high, moderate, or low on the basis of scientiﬁc
methodology, scientiﬁc strength, and consistency of
results. For CQ1 and CQ2, spreadsheets with rele-
vant data from systematic reviews and meta-analyses
were developed rather than summary tables.
 Used the graded ESs to write clinical recommendations,
and graded the strength of each recommendation. Rec-
ommendations were graded as Strong Recommenda-
tion (GradeA),ModerateRecommendation (GradeB),
Weak Recommendation (Grade C), Recommendation
Against (Grade D), Expert Opinion (Grade E), or
No Recommendation For or Against (Grade N).
 Performed Guideline Implementability Appraisals,
planned and coordinated by the NHLBI Imple-
mentation Work Group, to identify and address
barriers to guideline implementation.
1.4. Document Review and Approval
A formal peer review process was initially completed under
the auspices of the NHLBI and included 10 expert
reviewers and representatives from multiple federal
agencies. This document was also reviewed by 6 expert
reviewers nominated by the ACC, AHA, and The Obesity
Society after the management of the guideline transitioned
to the ACC/AHA. The ACC, AHA, and The Obesity
Society reviewers’ RWI information is published in this
document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACC, the AHA, and The Obesity So-
ciety and is endorsed by the American Association of
Cardiovascular and Pulmonary Rehabilitation, American
Pharmacists Association, American Society for Nutrition,
American Society for Parenteral and Enteral Nutrition,
American Society for Preventive Cardiology, American So-
ciety of Hypertension, Association of Black Cardiologists,
National LipidAssociation, PreventiveCardiovascularNurses
Association, The Endocrine Society, and WomenHeart:
The National Coalition for Women With Heart Disease.
2. Obesity Recommendations and Algorithm
2.1. Summary of Evidence-Based
Recommendations
The recommendations in Table 4 serve as a guide for
PCPs in making evaluations and treatment decisions for
Table 4. Summary of Recommendations for Obesity
Recommendations
NHLBI
Grade
NHLBI
ES ACC/AHA COR ACC/AHA LOE
Identifying Patients Who Need to Lose Weight (BMI and Waist Circumference)
1a. Measure height and weight and calculate BMI at annual visits or more frequently. E (Expert Opinion) CQ2 I C
1b. Use the current cutpoints for overweight (BMI 25.0–29.9 kg/m2) and obesity
(BMI 30 kg/m2) to identify adults who may be at elevated risk of
CVD and the current cutpoints for obesity (BMI 30 kg/m2) to identify adults who
may be at elevated risk of mortality from all causes.
A (Strong) CQ2 I B
1c. Advise overweight and obese adults that the greater the BMI, the greater the
risk of CVD, type 2 diabetes, and all-cause mortality.
A (Strong) CQ2 I B
1d. Measure waist circumference at annual visits or more frequently in
overweight and obese adults.
Advise adults that the greater the waist circumference, the greater the risk of CVD,
type 2 diabetes, and all-cause mortality. The cutpoints currently in common
use (from either NIH/NHLBI or WHO/IDF) may continue to be used to identify
patients who may be at increased risk until further evidence becomes available.
E (Expert Opinion) CQ2 IIa B
Matching Treatment Beneﬁts With Risk Proﬁles (Reduction in Body Weight Effect on Risk Factors for CVD, Events, Morbidity and Mortality)
2. Counsel overweight and obese adults with cardiovascular risk factors (high BP,
hyperlipidemia, and hyperglycemia) that lifestyle changes that produce even modest,
sustained weight loss of 3%–5% produce clinically meaningful health beneﬁts, and
greater weight losses produce greater beneﬁts.
a. Sustained weight loss of 3%–5% is likely to result in clinically meaningful
reductions in triglycerides, blood glucose, hemoglobin A1c, and the risk of
developing type 2 diabetes;
b. Greater amounts of weight loss will reduce BP, improve LDL–C and HDL–C, and
reduce the need for medications to control BP, blood glucose, and lipids as well
as further reduce triglycerides and blood glucose.
A (Strong) CQ1 I A
Diets for Weight Loss (Dietary Strategies for Weight Loss)
3a. Prescribe a diet to achieve reduced calorie intake for obese or overweight individuals
who would beneﬁt from weight loss, as part of a comprehensive lifestyle intervention.
Any one of the following methods can be used to reduce food and calorie intake:
a. Prescribe 1,200–1,500 kcal/d for women and 1,500–1,800 kcal/d for men
(kilocalorie levels are usually adjusted for the individual’s body weight);
b. Prescribe a 500-kcal/d or 750-kcal/d energy deﬁcit; or
c. Prescribe one of the evidence-based diets that restricts certain food types (such
as high-carbohydrate foods, low-ﬁber foods, or high-fat foods) in order to create
an energy deﬁcit by reduced food intake.
A (Strong) CQ3 I A
3b. Prescribe a calorie-restricted diet, for obese and overweight individuals who would
beneﬁt from weight loss, based on the patient’s preferences and health status, and
preferably refer to a nutrition professional* for counseling. A variety of dietary
approaches can produce weight loss in overweight and obese adults, as presented in
CQ3, ES2.
A (Strong) CQ3 I A
Continued on the next page
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evidence-based recommendations summarize current
literature on the risks of overweight and obesity and the
beneﬁts of weight loss. They also summarize knowledge on
the best diets for weight loss, the efﬁcacy and effectiveness
of comprehensive lifestyle interventions on weight loss and
weight loss maintenance, and the beneﬁts and risks of
bariatric surgery. This information will help PCPs decide
who should be recommended for weight loss and what
health improvements can be expected. The Expert Panel
did not choose a CQ that dealt with various aspects of
pharmacotherapy for a comprehensive evidence assess-
ment, because at the time the CQs were chosen there was
only one approved medication (orlistat) for weight loss.
However, CQ1 includes some ESs on the efﬁcacy of
orlistat because the effect of pharmacotherapy on weight
loss was included in its evidence review.2.2. Chronic Disease Management Model for
Primary Care of Patients With Overweight and
ObesitydTreatment Algorithm
The Expert Panel provides a treatment algorithm,
Chronic Disease Management Model for Primary Care
of Patients With Overweight and Obesity (Figure), to
guide PCPs in the evaluation, prevention, and manage-
ment of excess body weight in their patients. The
algorithm incorporates, wherever possible, the recom-
mendations derived from the 5 CQs that yielded ESs and
recommendations. However, because the 5 CQs that
were considered did not cover the entire scope of eval-
uation, prevention, and management of overweight/
obesity, the panelists provided advice based on other
guidelines and expert opinion to give providers a more
comprehensive approach to their patients with weight-
related issues.
Lifestyle Intervention and Counseling (Comprehensive Lifestyle Intervention)
4a. Advise overweight and obese individuals who would beneﬁt from weight loss to
participate for 6 months in a comprehensive lifestyle program that assists par-
ticipants in adhering to a lower-calorie diet and in increasing physical activity
through the use of behavioral strategies.
A (Strong) CQ4 I A
4b. Prescribe on-site, high-intensity (i.e., 14 sessions in 6 mo) comprehensive weight loss
interventions provided in individual or group sessions by a trained interventionist.y
A (Strong) CQ4 I A
4c. Electronically delivered weight loss programs (including by telephone) that include
personalized feedback from a trained interventionisty can be prescribed for weight
loss but may result in smaller weight loss than face-to-face interventions.
B (Moderate) CQ4 IIa A
4d. Some commercial-based programs that provide a comprehensive lifestyle
intervention can be prescribed as an option for weight loss, provided there is peer-
reviewed published evidence of their safety and efﬁcacy.
B (Moderate) CQ4 IIa A
4e. Use a very-low-calorie diet (deﬁned as <800 kcal/d) only in limited circumstances
and only when provided by trained practitioners in a medical care setting where
medical monitoring and high-intensity lifestyle intervention can be provided. Medical
supervision is required because of the rapid rate of weight loss and potential for
health complications.
A (Strong) CQ4 IIaz A
4f. Advise overweight and obese individuals who have lost weight to participate long
term (1 year) in a comprehensive weight loss maintenance program.
A (Strong) CQ4 I A
4g. For weight loss maintenance, prescribe face-to-face or telephone-delivered weight
loss maintenance programs that provide regular contact (monthly or more
frequently) with a trained interventionisty who helps participants engage in high
levels of physical activity (i.e., 200–300 min/wk), monitor body weight regularly (i.e.,
weekly or more frequently), and consume a reduced-calorie diet (needed to maintain
lower body weight).
A (Strong) CQ4 I A
Selecting Patients for Bariatric Surgical Treatment for Obesity (Bariatric Surgical Treatment for Obesity)
5a. Advise adults with a BMI 40 kg/m2 or BMI 35 kg/m2 with obesity-related
comorbid conditions who are motivated to lose weight and who have not responded
to behavioral treatment with or without pharmacotherapy with sufﬁcient weight loss
to achieve targeted health outcome goals that bariatric surgery may be an
appropriate option to improve health and offer referral to an experienced bariatric
surgeon for consultation and evaluation.
A (Strong) CQ5 IIax A
5b. For individuals with a BMI <35 kg/m2, there is insufﬁcient evidence to recommend
for or against undergoing bariatric surgical procedures.
N (No
Recommendation)
CQ5 d d
5c. Advise patients that choice of a speciﬁc bariatric surgical procedure may be affected
by patient factors, including age, severity of obesity/BMI, obesity-related comorbid
conditions, other operative risk factors, risk of short- and long-term complications,
behavioral and psychosocial factors, and patient tolerance for risk, as well as
provider factors (surgeon and facility).
E (Expert Opinion) CQ5 IIb C
*Nutrition professional: In the studies that form the evidence base for this recommendation, a registered dietitian usually delivered the dietary guidance; in most cases, the intervention was delivered in
university nutrition departments or in hospital medical care settings where access to nutrition professionals was available.
yTrained interventionist: In the studies reviewed, trained interventionists included mostly health professionals (e.g., registered dietitians, psychologists, exercise specialists, health counselors, or
professionals in training) who adhered to formal protocols in weight management. In a few cases, lay persons were used as trained interventionists; they received instruction in weight management
protocols (designed by health professionals) in programs that have been validated in high-quality trials published in peer-reviewed journals.
zThere is strong evidence that if a provider is going to use a very-low-calorie diet, it should be done with high levels of monitoring by experienced personnel; that does not mean that practitioners should
prescribe very-low-calorie diets. Because of concern that an ACC/AHA Class I recommendation would be interpreted to mean that the patients should go on a very-low-calorie diet, it was the consensus of
the Expert Panel that this maps more closely to an ACC/AHA Class IIa recommendation.
xThere is strong evidence that the beneﬁts of surgery outweigh the risks for some patients. These patients can be offered a referral to discuss surgery as an option. This does not mean that all patients
who meet the criteria should have surgery. This decision-making process is quite complex and is best performed by experts. The ACC/AHA criterion for a Class I recommendation states that the
treatment/procedure should be performed/administered. This recommendation as stated does not meet the criterion that the treatment should be performed. Thus, the ACC/AHA classiﬁcation criteria
do not directly map to the NHLBI grade assigned by the Expert Panel.
ACC indicates American College of Cardiology; AHA, American Heart Association; BMI, body mass index; BP, blood pressure; COR, Class of Recommendation; CQ, critical question; CVD, cardiovascular
disease; ES, evidence statement; HDL-C, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; NHLBI, National
Heart, Lung, and Blood Institute; NIH, National Health Institute; WHO, World Health Organization; and d, not applicable.
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2993The algorithm is not intended to supplant initial
assessment for cardiovascular risk factors or diseases but
rather focuses on the identiﬁcation of patients with excess
body weight and those at risk for obesity-related health
problems. Its purpose is to guide weight management
decision making.
The algorithm incorporates the recommendations from
CQ3 and CQ4 that patients who have sufﬁcient health riskfrom overweight or obesity receive comprehensive lifestyle
intervention. These approaches were all found effective
under conditions in which multidisciplinary teams of
medical, nutrition, and behavioral experts and other highly
trained professionals worked intensively with individuals
on weight management. This intervention should be
foundational to additional weight management efforts,
such as medications or bariatric surgery. It also emphasizes
Patient 
Encounter
(See Box 1)
Measure weight, 
height; calculate 
BMI
(See Box 2)
Yes
BMI ≥25
Assess and treat risk 
factors for CVD and 
obesity-related 
comorbidities
(See Box 4)
Assess weight and 
lifestyle histories
(See Box 5)
Advise to
avoid weight gain; 
address and treat 
other risk factors
(See Box 7)
No, insufficient risk
No, not yet ready
No
BMI 18.5-24.9
Measure weight 
and calculate BMI 
annually or more 
frequently
(See Box 17)
Follow-up and 
weight loss 
maintenance
(See Box 15)
Determine weight loss 
and health goals and 
intervention strategies
(See Box 9)
Comprehensive lifestyle 
intervention alone or 
with adjunctive therapies
 (BMI ≥30 or ≥27 with 
comorbidity)
(See Box 10)† 
High-intensity 
comprehensive 
lifestyle 
intervention
(See Box 11a)
Alternative delivery 
of lifestyle 
intervention
(See Box 11b)
BMI ≥30 or BMI ≥27 with 
comorbidity—option for adding 
pharmacotherapy as an adjunct to 
comprehensive lifestyle 
intervention
(See Box 12)†
BMI ≥40 or BMI ≥35 with comorbidity.
Offer referral to an experienced 
bariatric surgeon for consultation and 
evaluation as an adjunct to 
comprehensive lifestyle intervention
(See Box 13)
Yes
Yes
Yes
Continue intensive 
medical management of 
CVD risk factors and 
obesity-related 
conditions; weight 
management options
(See Box 19)
Intensive behavioral 
treatment (See Box 10); 
reassess and address 
medical or other 
contributory factors;  
consider adding or 
reevaluating obesity 
pharmacotherapy 
(See Box 12), and/or 
refer to an experienced 
bariatric surgeon
(See Box 13)
No
No
Yes, ready
Evaluation
Treatment
BMI 25-29.9 (overweight) 
or 30-34.9 (class I obese) 
or 35-39.9 (class II obese) 
or ≥40 (class III obese)
(See Box 3)
Assess need to 
lose weight: 
BMI ≥30 or BMI 25-29.9 
with risk factor(s)
(See Box 6)
Assess readiness to 
make lifestyle changes 
to achieve weight loss
(See Box 8)
Weight loss ≥5% 
and sufficient improvement 
in health targets
(See Box 14)
Weight 
loss ≥5% and sufficient  
improvement 
in health targets
(See Box 18)
Figure 1. Treatment AlgorithmdChronic Disease Management Model for Primary Care of Patients With Overweight and Obesity*
*This algorithm applies to the assessment of overweight and obesity and subsequent decisions based on that assessment. Each step (designated by a box) in this process is
reviewed in Section 2.2 and expanded on in subsequent sections.
yBMI cutpoint determined by the FDA and listed on the package inserts of FDA-approved obesity medications.
BMI indicates body mass index; CVD, cardiovascular disease; and FDA, U.S. Food and Drug Administration.
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3001a fundamental principle of chronic disease manage-
mentdthat is, the need to complement a committed pa-
tient with informed providers to effectively manage a
chronic condition like obesity and its associated cardio-
vascular risk factors.
3. CQs and Corresponding ESs
Each of the CQs are stated below, together with the
number of articles screened against their individual I/E
criteria and the number of articles that met the inclusion
criteria and were rated as fair or good quality. For
CQs that did not have many articles rated fair or good,
the articles rated as poor were used (i.e., CQ2). The
resulting ESs reﬂect the Expert Panel’s review of the
literature. The stated strength of evidence applies to the
overall ES, including any bulleted items, unless noted
otherwise.
3.1. CQ1: Statement of the Question
Among overweight and obese adults, does achieve-
ment of reduction in body weight with lifestyle and
pharmacological interventions affect cardiovascular risk
factors, CVD events, morbidity, and mortality?
1a. Does this effect vary across population subgroups
deﬁned by the following demographic and clinical
characteristics:
 Age
 Sex
 Race/ethnicity
 Baseline BMI
 Baseline waist circumference
 Presence or absence of comorbid conditions
 Presence or absence of cardiovascular risk factors1b. What amount (shown as percent lost, pounds lost,
etc.) of weight loss is necessary to achieve beneﬁt
with regard to cardiovascular risk factors,
morbidity, and mortality?
 Are there beneﬁts of cardiovascular risk factors,
CVD events, morbidity, and mortality from
weight loss?
 What are the beneﬁts of more signiﬁcant weight
loss?1c. What is the effect of sustained weight loss
for 2 years in individuals who are overweight
or obese, on cardiovascular risk factors,
CVD events, and health and psychological
outcomes?
 What percent of weight loss needs to be main-
tained at 2 years to be associated with health
beneﬁts?*Some papers were not appropriate for inclusion for reasons other than the criteria,
i.e., they did not address the question.CQ1 was initially intended to be a de novo systematic
review of original studies plus systematic reviews and
meta-analyses. Because of resource and time constraints,CQ1 was restricted to systematic reviews and meta-analyses
published only between January 2000 and October 2011.
The titles and abstracts of 1,630 publications were screened
against the I/E criteria independently by 2 reviewers, which
resulted in 669 publications being excluded and 697 publi-
cations being retrieved for full-text review to further assess
eligibility.* Six hundred ninety-seven full-text publica-
tions were independently screened by 2 reviewers, who
assessed eligibility by applying the I/E criteria; 669 of these
publications were excluded on the basis of 1 of the I/E
criteria. Of the 697 full-text publications, 42 publications
met the criteria and were included. The quality (internal
validity) of these 42 publications was assessed using the
quality assessment tool developed to assess systematic re-
views, meta-analyses, or RCTs. Of these, 14 publications
were rated as poor quality. The remaining 28 publications
were rated to be of good or fair quality and were included in
the evidence base that was used to formulate the ESs and
recommendations (12–39). Although the issue of phar-
macotherapy was not by itself a CQ, CQ1 was tasked to
evaluate this evidence, and several meta-analyses included
the effect of orlistat on weight loss and risk factors. None of
the systematic reviews or meta-analyses included the Look
AHEAD (Action for Health in Diabetes) trial data, which
the Expert Panel considered unique in that the number of
participants equaled or exceeded the total number of ob-
servations in most systematic reviews and meta-analyses.
The Look AHEAD papers were included in the database
as a critical supplement to the systematic review and meta-
analysis information. The ESs were developed from the
published literature available as of October 2011 and could
not take into account published or unpublished reports of
outcomes subsequent to the approval of the statements.
The following ESs reﬂect the Expert Panel’s review of
the literature. See the Full Panel Report supplement for the
supportive evidence and spreadsheets.
3.1.1. Weight Loss and Risk of Diabetes
ES1. In overweight and obese adults at risk for type 2
diabetes, average weight losses of 2.5 kg to 5.5 kg at 2
years achieved with lifestyle intervention (with or without
orlistat) reduce the risk of developing type 2 diabetes by
30% to 60%.
 Strength of Evidence: High
ES2. In overweight and obese adults with type 2 diabetes,
2% to 5% weight loss achieved with 1 to 4 years of lifestyle
intervention (with or without orlistat) results in modest
reductions in fasting plasma glucose concentrations and
lowering of hemoglobin A1c by 0.2% to 0.3%.
 Strength of Evidence: High
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3002ES3. In overweight and obese adults with type 2 diabetes,
those who achieve greater weight loss at 1 year with life-
style intervention (with or without orlistat) have greater
improvements in hemoglobin A1c. Weight loss of 5% to
10% is associated with hemoglobin A1c reductions of 0.6%
to 1.0% and reduced need for diabetes medications.
 Strength of Evidence: High
ES4. In overweight and obese adults with type 2 diabetes
treated for 1 year with lifestyle intervention (with or
without orlistat), those who lose more weight achieve
greater reductions in fasting plasma glucose concentrations.
Those who achieve weight losses of 2% to 5% are more
likely to have clinically meaningful (>20 mg/dL) re-
ductions in fasting glucose than those who remain weight
stable (deﬁned as gaining 2% or losing <2%).
 Strength of Evidence: High
ES5. As comprehensive lifestyle treatment of overweight
and obese adults with type 2 diabetes continues over
4 years, some weight regain will occur on average; partial
weight regain is associated with an increase in hemo-
globin A1c, but hemoglobin A1c remains below pre-
intervention levels, and the reduction remains clinically
meaningful (23).
 Strength of Evidence: Moderate
ES6. In observational cohort studies, overweight and obese
adults with type 2 diabetes who intentionally lost 9 kg to
13 kg had a 25% decrease in mortality rate compared with
weight-stable controls.
 Strength of Evidence: Low
ES7. In overweight and obese adults with type 2 diabetes,
orlistat with lifestyle intervention results in 2 kg to 3 kg
greater weight loss at 1 and 2 years than placebo with
lifestyle intervention. The addition of orlistat is associated
with greater reductions in fasting blood glucose, aver-
aging 11 mg/dL and 4 mg/dL at 1 and 2 years, as well as
an average greater reduction in hemoglobin A1c of 0.4%
at 1 year.
 Strength of Evidence: High
3.1.2. Weight Loss and Impact on
Cholesterol/Lipid Proﬁle
ES1. In overweight or obese adults with or without
elevated cardiovascular risk, there is a dose–response rela-
tionship between the amount of weight loss achieved by
lifestyle intervention and the improvement in lipid proﬁle.
The level of weight loss needed to observe these im-
provements varies by lipid as follows:
 At a 3 kg weight loss, a weighted mean reduction
in triglycerides of at least 15 mg/dL is observed. At 5 kg to 8 kg weight loss, low-density lipo-
protein cholesterol (LDL-C) reductions of
approximately 5 mg/dL and high-density lipo-
protein cholesterol (HDL-C) increases of 2 to 3
mg/dL are achieved.
 With <3 kg weight loss, more modest and more
variable improvements in triglycerides, HDL-C,
and LDL-C are observed.
 Strength of Evidence: High
ES2. Among overweight and obese adults with type 2
diabetes, 8.0% weight loss at 1 year and 5.3% weight loss
over 4 years, compared with usual care control, results in
greater average increases (2 mg/dL) in HDL-C and greater
average reductions in triglycerides.
 Strength of Evidence: Moderate
ES3. A mean 5% weight loss achieved over 4 years by life-
style intervention in overweight or obese adults with type 2
diabetes is associated with a reduction in newly pres-
cribed lipid-lowering medications compared with controls.
 Strength of Evidence: Moderate
ES4. Among overweight and obese adults with type 2
diabetes, there is a dose–response relationship between the
amount of weight loss and the increase in HDL-C, which
is most pronounced in those who are the least overweight
at baseline.
 Strength of Evidence: Low
ES5. Compared with placebo, the addition of orlistat to
lifestyle intervention in overweight and obese adults results
in an average 3 kg greater weight loss together with an 8 to
12 mg/dL reduction in LDL-C, a 1 mg/dL reduction in
HDL-C, and variable changes in triglycerides.
 Strength of Evidence: High
3.1.3. Weight Loss and Hypertension Risk
ES1. In overweight or obese adults with elevated cardio-
vascular risk (including type 2 diabetes and hypertension),
there is a dose–response relationship between the amount of
weight loss achieved at up to 3 years by lifestyle intervention
(alone or with orlistat) and the lowering of BP.
 At a 5% weight loss, a weighted mean reduction
in systolic and diastolic BP of approximately 3 and
2 mm Hg, respectively, is observed.
 At <5% weight loss, there are more modest and
more variable reductions in BP.
 Strength of Evidence: High
ES2. A 5% mean weight loss difference achieved over 4
years by intensive lifestyle intervention in overweight or
obese adults with type 2 diabetes is associated with a lower
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medications compared with controls.
 Strength of Evidence: Moderate
3.2. CQ2: Statement of the Question
2a. Are the current cutpoint values for overweight (BMI
25.0 to 29.9 kg/m2) and obesity (BMI 30 kg/m2),
compared with BMI 18.5 to 24.9 kg/m2, associated
with elevated CVD-related risk (deﬁned below)? Are
the waist circumference cutpoints of >102 cm (male)
and >88 cm (female) associated with elevated CVD-
related risk? How do these cutpoints compare with
other cutpoints in terms of elevated CVD-related risk
and overall mortality?
 Fatal and nonfatal CHD, stroke, and CVD (CHD
and stroke)
 Overall mortality
 Incident type 2 diabetes
 Incident dyslipidemia
 Incident hypertension2b. Are differences across population subgroups in the
relationships of BMI and waist circumference cut-
points with CVD, its risk factors, and overall mortality
sufﬁciently large to warrant different cutpoints? If so,
what should they be?
 Fatal and nonfatal CHD, stroke, and CVD
 Overall mortality
 Incident type 2 diabetes
 Incident dyslipidemia
 Incident hypertension
Groups being considered include:
 Age
 Sex (both male and female)
 Race/ethnicity (African American, Hispanic, Native
American, Asian, white)
2c. What are the associations between weight mainte-
nance and weight gain with elevated CVD-related risk
in normal-weight, overweight, and obese adults?
Because of resource limitations, the literature search for
CQ2 was limited to studies published between 2000 and
2011, and the evidence review limited to systematic re-
views, meta-analyses, and pooled analyses, to limit the
number of individual articles to be searched, reviewed, and
quality rated. Expert Panel members excluded studies that
focused on speciﬁc subpopulations with a disease
or condition (e.g., women with breast cancer, adults
on maintenance hemodialysis) and constructed summary
evidence tables from the identiﬁed articles, and these tables
were reviewed and checked by contractor staff for accuracy.
Of the 1,571 articles initially screened, 15 of the 482 full-
text publications met the I/E criteria and were included.
The quality (internal validity) of these 15 publications was
assessed using the quality assessment tool developed to
assess systematic reviews and meta-analyses. Of these, 3publications were rated as fair (40–42); the rest were rated
as poor quality but were included in the evidence base
because the NHLBI policy indicated that poor studies
could be used as part of the evidence base if the majority of
included studies were not rated good or fair. The following
ESs reﬂect the Expert Panel’s review of the literature.
3.2.1. Current BMI Cutpoints and CVD-Related Risk
and All-Cause Mortality
ES1. Among overweight and obese adults, analyses of
continuous BMI show that the greater the BMI, the higher
the risk of fatal CHD and combined fatal and nonfatal
CHD. The current cutpoints for overweight (BMI 25.0
kg/m2) and obesity (BMI 30 kg/m2) compared with
normal weight (BMI 18.5 to <25.0 kg/m2) are associated
with elevated risk of combined fatal and nonfatal CHD.
 Strength of Evidence: Moderate
ES2. Among overweight and obese adults, analyses of
continuous BMI show that the greater the BMI, the
higher the risk of fatal CHD and combined fatal and
nonfatal CHD in both men and women. The current BMI
cutpoints for overweight (BMI 25.0 kg/m2) and obesity
(BMI 30.0 kg/m2) compared with normal weight (BMI
18.5 to <25.0 kg/m2) are associated with elevated risk of
fatal CHD in both sexes.
 Strength of Evidence: Moderate
ES3. Among overweight or obese adults, analyses of
continuous BMI show that the greater the BMI, the
higher the risk of fatal stroke overall, as well as ischemic
and hemorrhagic stroke. The same relationship holds for
combined fatal and nonfatal ischemic stroke but across the
entire BMI range, not just in overweight and obese adults.
There is no evidence from meta-analyses, pooled analyses,
or systematic reviews to change current BMI cutpoints as
they relate to risk of stroke.
 Strength of Evidence: Moderate
ES4. Among overweight and obese adults, analyses of
continuous BMI show that the greater the BMI, the higher
the risk of combined fatal and nonfatal CVD. The current
cutpoint for obesity (BMI 30 kg/m2) compared with
normal weight (BMI 18.5 to 24.9 kg/m2) is associated with
an elevated risk of fatal CVD in men and women.
 Strength of Evidence: Moderate
ES5. In men only, the current BMI cutpoint for over-
weight (BMI 25.0 to 29.9 kg/m2) compared with normal
weight (BMI 18.5 to <25.0 kg/m2) is associated with an
elevated risk of fatal CVD. In both men and women,
obesity (BMI 30.0 kg/m2) compared with normal weight
is associated with an elevated risk of fatal CVD.
 Strength of Evidence: Low
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CVD was higher in obese white women than in obese
African-American women compared with normal-weight
women. In overweight women, there was no increase in
risk of fatal CVD compared with normal-weight women in
either race group.
 Strength of Evidence: Low
ES7. Analyses of continuous BMI across the entire BMI
range show that the greater the BMI, the higher the risk
of type 2 diabetes without an indication of a threshold
effect.
 Strength of Evidence: Moderate
ES8. Among overweight and obese adults, analyses of
continuous BMI show that the higher the BMI, the
greater the risk of all-cause mortality. The current cate-
gory for overweight (BMI 25.0 to 29.9 kg/m2) is not
associated with elevated risk of all-cause mortality, but
a BMI at or above the current cutpoint for obesity
(BMI 30 kg/m2) is associated with an elevated risk of
all-cause mortality, compared with normal weight (18.5
to 24.9 kg/m2).
 Strength of Evidence: Moderate
ES9. Sex-speciﬁc analyses of continuous BMI among
overweight and obese men and women show that the
greater the BMI, the higher the risk of all-cause mortality.
The risk of all-cause mortality associated with the current
cutpoints of obesity was similar for men and women.
 Strength of Evidence: Moderate
3.2.2. Areas of Insufﬁcient Evidence With Regard to
Cutpoints for BMI and for Waist Circumference
The Expert Panel was not able to address parts of CQ2
because of the lack of systematic reviews, meta-analyses,
and pooled analyses identiﬁed in the systematic search.
Expert Panel members were aware of a large body of
literature from individual studies examining the associa-
tions between BMI or waist circumference and hyperten-
sion or dyslipidemia, but these studies have not been
summarized in meta-analyses, pooled analyses, or system-
atic reviews that met the criteria. In addition, no studies in
the search compared alternative cutpoints with current
cutpoints as they relate to risk of CHD, stroke, CVD,
overall mortality, and diabetes. No systematic reviews,
meta-analyses, or pooled analyses were identiﬁed that
examined current waist circumference cutpoints as they
relate to the risk of all outcomes addressed in CQ2, but
the Expert Panel examined meta-analyses of studies that
used waist circumference as a continuous variable. There
is evidence from systematic reviews, meta-analyses, and
pooled analyses that risk factors increase in a continuous
manner with waist circumference. Because the Expert
Panel was unable to address issues of the adequacy ofcurrent waist circumference cutpoints for overweight and
obesity in comparison with alternative cutpoints, the choice
of cutpoints to apply in patient evaluation is somewhat
arbitrary. The Expert Panel was also unable to determine if
age-, sex-, or race-speciﬁc waist circumference cutpoints
for overweight and obesity are warranted to delineate
elevated risk of all outcomes examined in CQ2. The
absence of evidence from the available systematic reviews,
meta-analyses, and pooled analyses for waist circumference
cutpoints is not the same as the evidence of absence of
usefulness. The Expert Panel acknowledges that this
absence does not mean that waist circumference does not
provide useful information in certain circumstances. For
several of the outcomes, there were no analyses in the studies
retrieved that examined current BMI and waist circumfer-
ence cutpoints stratiﬁed by age, sex, and race-ethnicity.
Finally, there was a lack of these types of analyses exam-
ining the associations between weight maintenance and
weight gain with elevated cardiovascular risk in normal-
weight, overweight, and obese adults. For this reason, the
Expert Panel did not develop ESs addressing questions
related to these areas. The methodology team and sys-
tematic review team worked closely with Expert Panel
members to ensure the accuracy of data and the appli-
cation of systematic evidence-based methodology.3.3. CQ3: Statement of the Question
3a. In overweight or obese adults, what is the comparative
efﬁcacy/effectiveness of diets of differing forms and
structures (macronutrient content, carbohydrate and
fat quality, nutrient density, amount of energy deﬁcit,
and dietary pattern) or other dietary weight loss
strategies (e.g., meal timing, portion-controlled meal
replacements) in achieving or maintaining weight
loss?
3b. During weight loss or weight maintenance after
weight loss, what are the comparative health beneﬁts
or harms of the aforementioned diets and other dietary
weight loss strategies?
Of the 1,422 articles screened against the I/E criteria,
438 full-text articles were retrieved to further assess eligibility.
Of the 438 full-text publications, 77 publications met the
criteria and were included. A total of 17 trials (23 articles)
satisﬁed the ﬁnal inclusion criteria for CQ3 and were
rated to be of fair or good quality (43–65). The following
ESs reﬂect the Expert Panel’s review of the literature.
3.3.1. Overall Dietary Intervention and Compositiond
Creating Reduced Dietary Energy Intake
ES1. To achieve weight loss, an energy deﬁcit is required.
The techniques for reducing dietary energy intake include
the following:
 Speciﬁcation of an energy intake target that is less
than that required for energy balance, usually
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1,800 kcal/d for men (kilocalorie levels are usually
adjusted for the individual’s body weight and
physical activity levels);
 Estimation of individual energy requirements ac-
cording to expert guidelines (66–68) and pre-
scription of an energy deﬁcit of 500 kcal/d or 750
kcal/d or 30% energy deﬁcit; and
 Ad libitum approaches, in which a formal energy
deﬁcit target is not prescribed, but lower calorie
intake is achieved by restriction or elimination of
particular food groups or provision of prescribed
foods.
 Strength of Evidence: High
ES2. A variety of dietary approaches can produce weight
loss in overweight and obese adults. All of the following
dietary approaches (listed in alphabetical order) are asso-
ciated with weight loss if reduction in dietary energy intake
is achieved:
 A diet from the European Association for the
Study of Diabetes Guidelines, which focuses on
targeting food groups, rather than formal pre-
scribed energy restriction, while still achieving an
energy deﬁcit. Descriptions of the diet can be
found in the Full Panel Report supplement.
 Higher-protein diet (25% of total calories from
protein, 30% of total calories from fat, and 45% of
total calories from carbohydrate), with provision
of foods that realize an energy deﬁcit.
 Higher-protein Zone-type diet (5 meals/d, each
with 40% of total calories from carbohydrate, 30%
of total calories from protein, and 30% of total
calories from fat) without formal prescribed en-
ergy restriction but with a realized energy deﬁcit.
 Lacto–ovo–vegetarian–style diet with prescribed
energy restriction.
 Low-calorie diet with prescribed energy restriction.
 Low-carbohydrate diet (initially <20 g/d carbo-
hydrate) without formal prescribed energy re-
striction but with a realized energy deﬁcit.
 Low-fat vegan-style diet (10% to 25% of total
calories from fat) without formal prescribed en-
ergy restriction but with a realized energy deﬁcit.
 Low-fat diet (20% of total calories from fat)
without formal prescribed energy restriction but
with a realized energy deﬁcit.
 Low–glycemic–load diet, either with formal pre-
scribed energy restriction or without formal pre-
scribed energy restriction, but with realized energy
deﬁcit.
 Lower-fat (30% fat), high-dairy (4 servings/d)
diets with or without increased ﬁber and/or low-
glycemic-index (low–glycemic-load) foods with
prescribed energy restriction. Macronutrient-targeted diets (15% or 25% of
total calories from protein; 20% or 40% of total
calories from fat; 35%, 45%, 55%, or 65% of total
calories from carbohydrate) with prescribed
energy restriction.
 Mediterranean-style diet with prescribed energy
restriction.
 Moderate-protein diet (12% of total calories from
protein, 58% of total calories from carbohydrate,
and 30% of total calories from fat) with provision
of foods that realize an energy deﬁcit.
 Provision of high–glycemic-load or low–glycemic-
load meals with prescribed energy restriction.
 The AHA-style Step 1 diet (prescribed energy
restriction of 1,500 to 1,800 kcal/d, <30% of total
calories from fat, <10% of total calories from
saturated fat).
 Strength of Evidence: High
3.3.2. Overall Dietary Intervention and Compositiond
Pattern of Weight Loss Over Time
With Dietary Intervention
ES3. With dietary intervention in overweight and obese
adults, average weight loss is maximal at 6 months, with
smaller losses maintained for up to 2 years, while treatment
and follow-up tapers. Weight loss achieved by dietary
techniques aimed at reducing daily energy intake ranges
from 4 kg to 12 kg at 6-month follow-up. Thereafter, slow
weight regain is observed, with total weight loss at 1 year of
4 kg to 10 kg and at 2 years of 3 kg to 4 kg.
 Strength of Evidence: High
3.3.3. Low-Fat Approaches
ES4a. In overweight and obese adults, there is comparable
weight loss at 6 to 12 months with instruction to consume
a calorie-restricted (500- to 750-kcal deﬁcit/d) lower-fat
diet (<30% of total calories from fat) compared with
a higher-fat diet (>40% of total calories from fat).
Comprehensive programs of lifestyle change were used in
all trials. Comparator diets had 40% of total calories from
fat, either with a low-carbohydrate or low-glycemic-load
diet or one that targets higher fat with either average or
low protein.
 Strength of Evidence: Moderate
ES4b. With moderate weight loss, lower-fat, higher-
carbohydrate diets, compared with higher-fat, lower-
carbohydrate diets, have the following differential effects:
 Greater reduction in LDL-C,
 Lesser reduction in serum triglycerides, and
 Lesser increases in HDL-C.
 Strength of Evidence: Moderate
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ences between lower-fat, higher-carbohydrate diets and
higher-fat, lower-carbohydrate diets.
 Strength of Evidence: Low
3.3.4. Higher-Protein Approaches
(25% to 30% of Energy)
ES5a. In overweight and obese adults, recommendations
to increase dietary protein (25% of total calories) as part of
a comprehensive weight loss intervention results in weight
loss equivalent to that achieved with a typical protein diet
(15% of total calories) when both diets are calorie restricted
(500- to 750-kcal/d deﬁcit).
 Strength of Evidence: High
ES5b. In overweight and obese adults, high-protein diets
(25% of total calories) do not result in more beneﬁcial
effects on cardiovascular risk factors than typical protein
diets (15% of total calories) in the presence of weight loss
and other macronutrient changes.
 Strength of Evidence: Low
ES5c. On the basis of studies conducted in settings where
all food is provided to deliver increased protein (25% of
total calories) either as part of caloric restriction or with ad
libitum energy consumption, there is insufﬁcient evidence
to inform recommendations for weight loss interventions
in free-living overweight or obese individuals.
3.3.5. Low-Carbohydrate Approaches (<30 g/d)
ES6a. In overweight and obese adults, there are no dif-
ferences in weight loss at 6 months with instructions to
consume a carbohydrate-restricted diet (20 g/d for up to
3 months, followed by increasing levels of carbohydrate
intake up to a point at which weight loss plateaus) in
comparison with instruction to consume a calorie-
restricted, low-fat diet. The comparator diets on which
this statement is based were either a calorie-restricted,
higher-carbohydrate, and lower-protein diet (55% of total
calories from carbohydrate, 30% of total calories from fat,
and 15% of total calories from protein) or a lower-fat
European Association for the Study of Diabetes food
group dietary pattern (40% of total calories from carbo-
hydrate, 30% of total calories from fat, and 30% of total
calories from protein).
 Strength of Evidence: Low
ES6b. There is insufﬁcient evidence to comment on the
cardiovascular risk factor effects of low-carbohydrate diets.
3.3.6. Complex Versus Simple Carbohydrates
ES7. There is insufﬁcient evidence to comment on
the value of substituting either simple or complex carbo-
hydrates for dietary fat in overweight or obese adults for the
purpose of weight reduction.3.3.7. Glycemic Load Dietary Approaches
ES8. In overweight and obese adults, both high– and low–
glycemic-load diets produce a comparable weight loss with
a similar rate of loss over 6 months.
 Strength of Evidence: Low
3.3.8. Dietary Patterns (Mediterranean Style,
Vegetarian, and Other Dietary Pattern Approaches)
ES9. In overweight and obese adults, a variety of calorie-
restricted dietary patterns (e.g., Mediterranean-style diet,
lower-fat lacto–ovo-vegetarian or vegan-style diet, or
lower-fat diet with high dairy/calcium with added ﬁber
and/or low–glycemic-index [low–glycemic-load] foods)
produce weight loss and cardiovascular beneﬁts that are
comparable to an energy-restricted, lower-fat dietary
pattern (25% to 30% of total calories from fat; Adult
Treatment Panel III or AHA Step 1).
 Strength of Evidence: Low
3.3.9. Meal Replacement and Adding Foods
to Liquid Diets
ES10a. In overweight and obese women, the use of liquid
and bar meal replacements is associated with increased
weight loss at up to 6 months, in comparison with a
balanced deﬁcit diet using only conventional food. Longer-
term evidence of continued weight loss advantage is lacking.
 Strength of Evidence: Low
ES10b. There is insufﬁcient evidence to comment on the
value of adding various types of foods to a low-calorie
liquid diet.
3.3.10. Very-Low-Calorie Diet Approaches
ES11a. There is insufﬁcient evidence to comment on the
value of liquid protein supplementation after the very–low-
calorie diet induction of weight loss as an aid to weight loss
maintenance.
ES11b. There is insufﬁcient evidence to comment on
strategies to provide more supervision of very–low-calorie
diet adherence or to liberalize very–low-calorie diet therapy
with the addition of conventional foods as an aid to the
induction of weight loss.
3.4. CQ4: Statement of the Question
4a. Among overweight and obese adults, what is the ef-
ﬁcacy/effectiveness of a comprehensive lifestyle inter-
vention program (i.e., comprised of diet, physical
activity, and behavior therapy) in facilitating weight
loss or maintenance of lost weight?
4b. What characteristics of delivering comprehensive
lifestyle interventions (e.g., frequency and duration of
treatment, individual versus group sessions, on site
versus telephone/email contact) are associated with
greater weight loss or weight loss maintenance?
yTrained interventionist: In the studies reviewed, trained interventionists included
mostly health professionals (e.g., registered dietitians, psychologists, exercise spe-
cialists, health counselors, or professionals in training) who adhered to formal
protocols in weight management. In a few cases, lay persons were used as trained
interventionists; they received instruction in weight management protocols
(designed by health professionals) in programs that have been validated in high-
quality trials published in peer-reviewed journals.
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comprehensive intervention initially including 2 or more
components (dietary prescription, physical activity, or
behavioral therapy) to all 3 components being required.
Additional exclusion criteria were later put in place to
remove trials that included comprehensive lifestyle in-
terventions but were designed principally to compare
different dietary interventions. The Expert Panel decided
that such trials were more appropriately addressed under
CQ3. The titles and abstracts of 2,160 publications were
screened against the I/E criteria independently by 2 re-
viewers (i.e., independent contractors), which resulted in
1,776 publications being excluded and 384 publications
being retrieved for full-text review to further assess eligi-
bility. Three hundred eighty-four full-text publications
were independently screened by 2 reviewers who assessed
eligibility by applying the I/E criteria; 215 of these pub-
lications were excluded on the basis of 1 of the I/E
criteria.
Out of 384 full-text publications, 146 publications met
the criteria and were included. The quality (internal val-
idity) of these 146 publications was assessed using the
quality assessment tool developed to assess RCTs. Of
these, 74 publications were excluded because they were
rated as poor quality; of those 74 publications, 43 studies
were rated poor because of the intention-to-treat and
attrition rates. The remaining 51 trials (72 articles) were
rated to be of good or fair quality (22,23,69–138) and were
included in the evidence base that was used to formulate
the following ESs and recommendations.
3.4.1. Description of the Diet, Physical Activity, and
Behavior Therapy Components in High-Intensity,
On-Site Lifestyle Interventions
ES1. The principal components of an effective high-
intensity, on-site comprehensive lifestyle intervention
include 1) prescription of a moderately reduced-calorie
diet, 2) a program of increased physical activity, and 3)
the use of behavioral strategies to facilitate adherence to
diet and activity recommendations. All 3 components
should be included:
 Reduced-calorie diet: In comprehensive lifestyle
interventions, overweight/obese individuals typi-
cally are prescribed a diet designed to induce an
energy deﬁcit of 500 kcal/d. This deﬁcit often
is sought by prescribing 1,200 to 1,500 kcal/d for
women and 1,500 to 1,800 kcal/d for men.
Alternatively, dietary energy deﬁcits can be deter-
mined by one of the methods described in CQ3.
 Increased physical activity: Comprehensive life-
style intervention programs typically prescribe
increased aerobic physical activity (such as brisk
walking) for 150 min/wk (equal to 30 min/d
most days of the week). Higher levels of physical
activity, approximately 200 to 300 min/wk, arerecommended to maintain lost weight or minimize
weight regain in the long term (>1 year).
 Behavior therapy: Comprehensive lifestyle
interventions usually provide a structured behavior
change program that includes regular self-
monitoring of food intake, physical activity, and
weight. These same behaviors are recommended
to maintain lost weight, with the addition of
frequent (i.e., weekly or more often) monitoring
of body weight.
 Strength of Evidence: High
3.4.2. Comprehensive Interventions Compared With
Usual Care, Minimal Care, or No-Treatment Control
ES2a (Short-Term Weight Loss). In overweight and
obese individuals in whom weight loss is indicated and
who wish to lose weight, comprehensive lifestyle in-
terventions consisting of diet, physical activity, and behavior
therapy (all 3 components) produce average weight losses
of up to 8 kg in 6 months of frequent (i.e., initially
weekly) on-site treatment provided by a trained inter-
ventionisty in group or individual sessions. Such losses
(which can approximate reductions of 5% to 10% of initial
weight) are greater than those produced by usual care (i.e.,
characterized by the limited provision of advice or educa-
tional materials). Comparable 6-month weight losses
have been observed in treatment-comparison studies of
comprehensive lifestyle interventions, which did not
include a usual-care control group.
 Strength of Evidence: High
ES2b (Intermediate-Term Weight Loss). Longer-term
comprehensive lifestyle interventions, which additionally
provide weekly to monthly on-site treatment for another
6months, produce averageweight losses of up to8kg at 1 year,
losses that are greater than those resulting from usual care.
Comparable 1-year weight losses have been observed in
treatment-comparison studies of comprehensive lifestyle in-
terventions, which did not include a usual-care control group.
 Strength of Evidence: Moderate
ES2c (Long-Term Weight Loss). Comprehensive life-
style interventions that, after the ﬁrst year, continue to
provide bimonthly or more frequent intervention con-
tacts, are associated with gradual weight regain of 1 to
2 kg/y (on average) from the weight loss achieved at 6 to
12 months. Long-term (>1 y) weight losses, however,
remain larger than those associated with usual care.
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comparison studies of comprehensive lifestyle inter-
ventions, which did not include a usual-care control
group.
 Strength of Evidence: High
3.4.3. Efﬁcacy/Effectiveness of Electronically
Delivered, Comprehensive Interventions in
Achieving Weight Loss
ES3. Electronically delivered, comprehensive weight loss
interventions developed in academic settings, which include
frequent self-monitoring of weight, food intake, and
physical activitydas well as personalized feedback from a
trained interventionistydcan produce weight loss of up to 5
kg at 6 to 12 months. This loss is greater than that resulting
from no or minimal intervention (i.e., primarily knowledge
based) offered on the Internet or in print.
 Strength of Evidence: Moderate
3.4.4. Efﬁcacy/Effectiveness of Comprehensive,
Telephone-Delivered Lifestyle Interventions in
Achieving Weight Loss
ES4. In comprehensive lifestyle interventions that are
delivered by telephone or face-to-face counseling and
that also include the use of commercially-prepared pre-
packaged meals or an interactive Web-based program,
the telephone-delivered and face-to-face–delivered in-
terventions produce similar mean net weight losses of
approximately 5 kg at 6 months and 24 months, compared
with a usual-care control group.
 Strength of Evidence: Low
3.4.5. Efﬁcacy/Effectiveness of Comprehensive Weight
Loss Programs in Patients Within a Primary Care
Practice Setting Compared With Usual Care
ES5. In studies to date, low- to moderate-intensity life-
style interventions for weight loss provided to overweight
or obese adults by primary care practices alone have not
been shown to be effective.
 Strength of Evidence: High
3.4.6. Efﬁcacy/Effectiveness of Commercial-Based,
Comprehensive Lifestyle Interventions in Achieving
Weight Loss
ES6. Commercial-based, comprehensive weight loss in-
terventions that are delivered in person have been shown to
induce an average weight loss of 4.8 kg to 6.6 kg at
6 months in 2 trials when conventional foods are consumed
and 6.6 kg to 10.1 kg at 12 months in 2 trials with provision
of prepared food. These losses are greater than those pro-
duced by minimal-treatment control interventions.
 Strength of Evidence: Low3.4.7. Efﬁcacy/Effectiveness of Very–Low-Calorie
Diets as Used as Part of a Comprehensive Lifestyle
Intervention in Achieving Weight Loss
ES7a. Comprehensive, high-intensity, on-site lifestyle
interventions that include a medically supervised very–low-
calorie diet (often deﬁned as <800 kcal/d), as provided by
complete meal replacement products, produce total weight
loss of approximately 14.2 kg to 21.0 kg over 11 to 14
weeks, which is larger than that produced by no inter-
vention or usual care (i.e., advice and education only).
 Strength of Evidence: High
ES7b. After the cessation of a high-intensity lifestyle
intervention with a medically supervised very–low-calorie
diet of 11 to 14 weeks, weight regain of 3.1 kg to 3.7 kg
has been observed during the ensuing 21 to 38 weeks of
nonintervention follow-up.
 Strength of Evidence: High
ES7c. The prescription of various types (resistance or
aerobic training) and doses of moderate-intensity exercise
training (e.g., brisk walking 135 to 250 min/wk) delivered
in conjunction with weight loss maintenance therapy does
not reduce the amount of weight regained after the
cessation of the very–low-calorie diet, compared with
weight loss maintenance therapy alone.
 Strength of Evidence: Low3.4.8. Efﬁcacy/Effectiveness of Comprehensive
Lifestyle Interventions in Maintaining Lost Weight
ES8a. After initial weight loss, some weight regain can
be expected, on average, with greater regain observed
over longer periods of time. Continued provision of a
comprehensive weight loss maintenance program (on site
or by telephone) for periods of up to 2.5 years after initial
weight loss reduces weight regain, as compared with the
provision of minimal intervention (i.e., usual care). The
optimal duration of weight loss maintenance programs has
not been determined.
 Strength of Evidence: Moderate
ES8b. Of overweight/obese adults who participate in a
high-intensity long-term comprehensive lifestyle inter-
vention, 35% to 60% maintain a loss of 5% of initial
body weight at 2 years’ follow-up (after randomization).
 Strength of Evidence: Moderate
3.4.9. Characteristics of Lifestyle Intervention Delivery
That May Affect Weight Loss: Intervention Intensity
ES9a (Moderate-Intensity Interventions). Moderate-
intensity, on-site comprehensive lifestyle interventions,
which provide an average of 1 to 2 treatment sessions per
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4 kg in 6 to 12 months. These losses generally are greater
than those produced by usual care (i.e., minimal-
intervention control group).
 Strength of Evidence: High
ES9b (Low-Intensity Interventions). Low-intensity, on-
site comprehensive lifestyle interventions, which provide
less-than-monthly treatment sessions, do not consistently
produce weight loss when compared with usual care.
 Strength of Evidence: Moderate
ES9c (Effect of Intervention Intensity). When weight
loss with each intervention intensity (i.e., low, moderate,
and high) is compared with usual care, high-intensity
lifestyle interventions (14 sessions in 6 months) typi-
cally produce greater net-of-control weight losses than do
low- to moderate-intensity interventions.
 Strength of Evidence: Moderate
3.4.10. Characteristics of Lifestyle Intervention
Delivery That May Affect Weight Loss or Weight Loss
Maintenance: Individual Versus Group Treatment
ES10. There do not appear to be substantial differences in
the size of the weight losses produced by individual- and
group-based sessions in high-intensity, comprehensive
lifestyle intervention delivered on site by a trained
interventionist.y
 Strength of Evidence: Low
3.4.11. Characteristics of Lifestyle Intervention
Delivery That May Affect Weight Loss or Weight Loss
Maintenance: On-Site Versus Electronically Delivered
Interventions
ES11. Weight losses observed in comprehensive lifestyle
interventions, which are delivered on site by a trained
interventionisty in initially weekly and then biweekly group
or individual sessions, are generally greater than weight
losses observed in comprehensive interventions that are
delivered by Internet or email and that include feedback
from a trained interventionist.
 Strength of Evidence: Low
3.5. CQ5: Statement of the Question
5a. Bariatric Surgery Efﬁcacy. What are the long-term
effects of the following surgical procedures on weightyTrained Interventionist: In the studies reviewed, trained interventionists included
mostly health professionals (e.g., registered dietitians, psychologists, exercise spe-
cialists, health counselors, or professionals in training) who adhered to formal
protocols in weight management. In a few cases, lay persons were used as trained
interventionists; they received instruction in weight management protocols
(designed by health professionals) in programs that have been validated in high-
quality trials published in peer-reviewed journals.loss, weight loss maintenance, cardiovascular risk fac-
tors, related comorbidities, and mortality?
 Laparoscopic adjustable gastric banding (LAGB)
 Laparoscopic Roux-en-Y gastric bypass (RYGB)
 Open RYGB
 Biliopancreatic diversion (BPD) with and without
duodenal switch
 Sleeve gastrectomy
What are the long-term effects of these surgical
procedures in patients with different BMIs and
comorbidities?
 BMI <35
 BMI 35 to <40 with no comorbidities
 BMI 35 with comorbidities
 BMI 40 with no comorbidities5b. Predictors. What are the predictors associated with
long-term effects of the following surgical pro-
cedures on weight loss, weight loss maintenance,
cardiovascular risk factors, related comorbidities, and
mortality?
 LAGB
 Laparoscopic RYGB
 Open RYGB
 BPD with and without duodenal switch
 Sleeve gastrectomy
What are the predictors associated with long-term
effects of these surgical procedures in patients with
different BMIs and comorbidities?
 BMI <35
 BMI 35 to <40 with no comorbidities
 BMI 35 with comorbidities
 BMI 40 with no comorbidities5c. Complications: What are the short-term (<30 days)
and long-term (30 days) complications of the
following bariatric surgical procedures? What are the
predictors associated with complications?
 LAGB
 Laparoscopic RYGB
 Open RYGB
 BPD with and without duodenal switch
 Sleeve gastrectomy
What are the complications of these surgical
procedures in patients with different BMIs and
comorbidities?
 BMI <35
 BMI 35 to <40 with no comorbidities
 BMI 35 with comorbidities
 BMI 40 with no comorbiditiesMany, if not most, patients with extreme obesity have
tried to lose weight numerous times. Some have lost sub-
stantial amounts of weight successfully, only to regain it.
Although lifestyle intervention is the mainstay of all weight
management treatment, there is increasing recognition of
the need for adjunctive treatments for patients with obesity
who are at highmedical risk andwho are unable to achieve or
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Bariatric surgery is one treatment option that has been
increasingly used in patients with extreme obesity or with
lesser degrees of obesity but with obesity-related comorbid
conditions. Bariatric surgery is, by deﬁnition, invasive and
has inherent short-term risks as well as adverse effects that
may become apparent only during longer-term follow-up.
Incurring these risks may be acceptable if health beneﬁts are
sustained over time. Therefore, the Expert Panel believed
that evaluation of efﬁcacy endpoints for weight loss and
change in cardiovascular risk factors and other health out-
comes required studies with aminimum postsurgical follow-
up of 2 years and inclusion of a nonsurgical comparator
group. Studies evaluating predictors of weight change or
medical outcomes, including patient factors (e.g., presence
or absence of diabetes) or surgical factors (e.g., RYGB
versus BPD) required studies that directly compared these
factors plus a minimum 2-year follow-up. Studies evalu-
ating complications of bariatric surgery required at least
30-day postsurgical follow-up. For observational studies
with10 years of follow-up or for studies on BPD or sleeve
gastrectomy procedures, sample size 100 was required,
and for all other observational studies the sample size
requirement was 500. This sample size requirement was
instituted because the most important complications are
infrequent (e.g., perioperative mortality <1%), such that
smaller studies could give inaccurate estimates of compli-
cation rates.
The literature search for CQ5 included an electronic
search for RCTs, controlled clinical trials, and observa-
tional studies published in the literature from January 1998
to December 2009. The search produced 2,317 citations,
with 9 additional citations identiﬁed from nonsearch
sourcesdthat is, by Expert Panel members or hand search
of systematic reviews and meta-analyses (obtained through
the electronic search). Of the 2,317 citations identiﬁed
through the database search, 811 citations were automat-
ically excluded, and the titles and abstracts of the 1,515
remaining citations were screened against the I/E criteria
for each of the 3 components (efﬁcacy, predictors, and
complications) independently by 2 reviewers, which
resulted in 1,062 publications being excluded. Of the
remaining 453 full-text publications, 64 met the I/E
criteria, underwent full text review, and were included. The
quality (internal validity) of these 64 publications was
assessed, and of these, 29 publications were excluded
because they were rated as poor quality; 18 studies were
rated poor because of the intent-to-treat and/or attrition
rates. The remaining 22 studies (35 articles) that met the
criteria for at least 1 of the 3 components were rated good
or fair quality and included in the evidence base (139–173).
For the efﬁcacy, predictors, and complications compo-
nents, 5 studies (17 articles), 10 studies (12 articles) and 14
studies (15 articles) were rated as good/fair, respectively. A
total of 8 articles were used across more than 1 component
(141,142,144,148,156,159,168,169).3.5.1. Component 1: Efﬁcacy
A total of 5 studies (17 articles) met the criteria for
determining the efﬁcacy of bariatric surgery for weight loss
and the impact on obesity-related comorbidities, were
rated as good or fair quality, and are included in the
summary table. The number of studies meeting inclusion
criteria was limited because of the requirement that sur-
gical treatment be compared with a nonsurgical compar-
ator group with a minimum postsurgical follow-up of
2 years.ES1. In obese adults, bariatric surgery produces greater
weight loss and weight loss maintenance than that pro-
duced by usual care, conventional medical treatment, life-
style intervention, or medically supervised weight loss, and
weight loss efﬁcacy varies depending on the type of pro-
cedure and initial body weight. Weight loss at 2 to 3 years after a variety of sur-
gical procedures in adults with presurgical
BMI 30 varies from a mean of 20% to 35% of
initial weight and mean difference from nonsur-
gical comparators of 14% to 37%, depending on
procedure.
 Strength of Evidence: High
 Mean weight loss at 10 years after a variety of
bariatric surgical procedures (predominantly ver-
tical banded gastroplasty) is approximately 16% of
initial weight, representing a mean weight regain
of 7%.
 Strength of Evidence: Low
ES2. In obese adults, bariatric surgery generally results in
more favorable impact on obesity-related comorbid con-
ditions than that produced by usual care, conventional
medical treatment, lifestyle intervention, or medically su-
pervised weight loss. At 2 to 3 years after a variety of bariatric surgical
procedures in adults with BMI 30 who achieve
mean weight loss of 20% to 35%, fasting glucose
and insulin are reduced and incidence of type 2
diabetes is decreased, and there is a greater like-
lihood of diabetes remission among those with
type 2 diabetes at baseline.
 Strength of Evidence: High
 At 10 years, incidence and prevalence of type 2
diabetes are lower in those who have undergone
surgery. However, among those in whom type 2
diabetes remits after surgery, diabetesmay recur over
time.
 Strength of Evidence: Low
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procedures in adults with BMI 30 who achieve
mean weight loss of 20% to 35%, BP or use of BP
medication is reduced compared with nonsurgical
management. BP tends to increase over time, and
at 10 years after surgery, there is no difference in
mean systolic BP or the incidence of new cases of
hypertension in those who have undergone bar-
iatric surgery compared with those who have not
undergone surgery.
 Strength of Evidence: Low
 Among obese adults with baseline hypertension, a
greater percentage are in remission at 2 to 3 years
and 10 years after bariatric surgery compared with
nonsurgical management.z
 Strength of Evidence: Low At 2 to 3 years and 10 years after a variety of bariatric
surgical procedures in adults with BMI 30 who
achieve mean weight loss of 20% to 35%, serum
triglyceride levels are lower, HDL-C levels are
higher, ratio of total cholesterol to HDL-C is
lower, and changes in total cholesterol or LDL
levels are inconsistent, compared with nonsurgical
management.
 Strength of Evidence: Low
 Most measures of health-related quality of life are
improved at 2 and 10 years after bariatric surgery.
 Strength of Evidence: Moderate
 Total mortality is decreased compared with
nonsurgical management at mean follow-up of 11
years after undergoing a variety of bariatric surgical
procedures (predominantly vertical banded gas-
troplasty) in patients with mean BMI >40 who
achieve a mean long-term weight loss of 16%.
 Strength of Evidence: Low
ES3. There are insufﬁcient data on the efﬁcacy of bariatric
surgical procedures for weight loss and maintenance or risk
factors for CVD 2 years after surgery in patients with a
BMI <35.
3.5.2. Component 2: Predictors
A total of 10 studies (12 articles) met the inclusion criteria,
were rated as good or fair quality, and are included in the
summary table (141,142,144,148,151,155,156,159,161,168,
169,172). The studies were required to have a comparator
group but not necessarily a nonsurgical comparator, as well
as outcomes of speciﬁc bariatric operative procedures.zRemission was deﬁned variously depending on the study.ES4. Weight loss after bariatric surgery expressed as per-
centage of total body weight loss varies by procedure.
In direct comparative studies at 2 to 3 years after surgery: Weight loss after gastric bypass exceeds that
achieved after LAGB.
 Strength of Evidence: Moderate
 Weight losses after BPD, gastric bypass, and
sleeve gastrectomy are similar.
 Strength of Evidence: Low
In direct comparative studies at 5 to 10 years after
surgery: Weight loss after gastric bypass exceeds that
achieved after LAGB.
 Strength of Evidence: LowES5. The remission of obesity-related comorbidities varies
by procedure. Type 2 diabetes remission or improved glycemic
control occurswith increasing frequency according to
procedure as follows: LAGB, gastric bypass, BPD.
 Strength of Evidence: Low
 Reduction in the prevalence of hypertension ismore
frequent after gastric bypass than after LAGB.
 Strength of the Evidence: Low
 The prevalence of dyslipidemia is lower after
gastric bypass than after LAGB.
 Strength of Evidence: Low
3.5.3. Component 3: Complications
Fourteen studies met the inclusion criteria for com-
plications. The complication evidence base included those
studies from the efﬁcacy and predictors searches that
included complication data (141,156), as well as those
studies that met the expanded search criteria
(139,143,145,146,152,153,160,170,171).
3.5.3.1. LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING
ES6. Perioperative (30 day) and longer-term (>30 days)
complications after bariatric surgery vary by procedure and
patient-derived risk factors. When LAGB is performed by
an experienced surgeon: Perioperative complications are infrequent and do
not tend to be life-threatening: major adverse
outcomes (1%), such as deep venous thrombosis
and reoperations, and minor complications (3%),
such as wound infection.
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 Longer-term complications continue to occur over
time and may require operative correction:
misplacement of band, approximately 3% to 4%;
erosion of gastric wall, approximately 1%; and port
complication, 5% to 11%.
 Strength of Evidence: Moderate
 The rate of longer-term LAGB failure leading to
removal of the band with or without conversion to
another bariatric procedure varies from 2% to
34%. Inadequate weight loss is the most often
reported basis for removal of band.
 Strength of Evidence: Moderate
3.5.3.2. ROUX-EN-Y GASTRIC BYPASS
ES6 (continued). Perioperative (30 days) and longer-
term (>30 days) complications after bariatric surgery vary
by procedure and patient-derived risk factors. When
gastric bypass is performed by an experienced surgeon: Perioperative complications consist of a major
adverse outcome in approximately 4% to 5% of
patients, including mortality (0.2%), deep vein
thrombosis and/or pulmonary embolism (0.4%),
and a need for reoperation (3% to 5%). The rate of
any complication, major or minor, is 2% to 18%.
 Strength of Evidence: Moderate
 Perioperative complications are less frequent for
the laparoscopic approach than for open incision.
 Strength of Evidence: Moderate
When open gastric bypass is performed by an experi-
enced surgeon: Perioperative complications consist of a major
adverse outcome in approximately 8% of patients,
including mortality (2%), deep vein thrombosis or
pulmonary embolism (1%), and a need for reop-
eration (5%).
 Strength of Evidence: Low
 Perioperative complications are associated with
extremely high BMI, inability to walk 200 feet,
history of deep vein thrombosis or pulmonary
embolism, and history of obstructive sleep apnea.
 Strength of the Evidence: Low
3.5.3.3. BILIOPANCREATIC DIVERSION
ES6 (continued). Perioperative (30 days) and longer-
term (>30 days) complications after bariatric surgery vary
by procedure and patient-derived risk factors. Themortality rate for BPD was reported by 2 of the 3 included
studies. When BPD is performed by an experienced
surgeon: Perioperative complications occur in 2% to 8% of
cases and include mortality (<1%) and deep vein
thrombosis or pulmonary embolism (0.4%). The
frequency of anastomotic leak, hemorrhage, and
wound complication is variable.
 Strength of the Evidence: Low
 One- to three-year complications include: anemia
(13% to 20%); deﬁciency of protein (0.3% to
3.0%), iron (17%), or zinc (6%); and neuropathy
(0.4%). Deﬁciency of vitamin D and elevated
parathyroid hormone may exceed 40%.
 When BPD is performed by open incision, the
rate of ventral hernia can be as high as 72%.
 Strength of the Evidence: Low
3.5.3.4. LAPAROSCOPIC SLEEVE GASTRECTOMY
ES6 (continued). Perioperative (30 days) and longer-term
(>30 days) complications after bariatric surgery vary by pro-
cedure and patient-derived risk factors. When laparoscopic
sleeve gastrectomy is performed by an experienced surgeon: There is insufﬁcient evidence to establish the
incidence of perioperative and longer-term
complications.4. Gaps in Evidence and
Future Research Needs
The Expert Panel identiﬁed gaps in evidence supporting
the 5 chosen CQs. For each CQ, the Expert Panel sum-
marized recommendations for future research. See the
Full Panel Report supplement for a more detailed and
comprehensive discussion.
4.1. CQ1 (Beneﬁts of Weight Loss)
The literature available in systematic reviews and meta-
analyses did not speciﬁcally address whether age, sex,
race, or baseline BMI or waist circumference modiﬁes the
beneﬁcial effects of weight loss on cardiovascular risk
factors. Likewise, the systematic reviews and meta-
analyses did not speciﬁcally address the issue of how
baseline comorbid conditions and cardiovascular risk
factors modify the response to weight loss. Nevertheless,
high-quality literature that addresses these issues could
exist. Given that caveat and the present evidence review,
future research in this area should address the following
issues:
1. Do the observed improvements in cardiovascular risk
factors, need for medications, and improved quality
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race, or BMI or waist circumference?
2. What is the cost-effectiveness of modest weight loss
as a preventive strategy for those at risk of developing
type 2 diabetes?
3. What is the best approach to identify and engage
those who can beneﬁt from weight loss?4.2. CQ2 (Risks of Overweight and Obesity)
Because evidence-based methods to identify patients with
elevated risk for CVD, its risk factors, and all-cause
mortality are essential for healthcare practitioners, more
systematic reviews, meta-analyses, and pooled analyses
are needed to inform future guidelines in the following
areas:
 Studies are needed that compare current BMI and
waist circumference cutpoints with alternative cut-
points for predicting risk to optimize the speciﬁcity
of cutpoints.
 Studies should examine the independent and
combined effects of BMI and waist circumfer-
ence to determine if both in combination are
better at predicting elevated risk than either
alone.
 Such studies should explicate the methods and
logical framework that guides the choice of
optimal cutpoints.
 Studies comparing the predictive ability of BMI
and waist circumference with more objective
measures of percent body fat, such as dual-
energy x-ray absorptiometry or magnetic reso-
nance imaging, may enhance risk prediction of
cutpoints and/or combinations of BMI and waist
circumference.
 Similar studies are needed to assess whether overall
cutpoints are appropriate for population subgroups
stratiﬁed by age, sex, and race/ethnicity.
 Studies that compare risk across different age
groups should report absolute risk estimates. This
is especially important when examining age.
 Studies are needed on racial-ethnic differences in
risk within Western countries, particularly in
Asian Americans and Hispanic Americans.
 Longitudinal studies are needed that assess the risks
associated with weight change (accounting for
intentionality) in normal-weight, overweight, and
obese adults to determine the role of weight change
trajectory in risk assessment.4.3. CQ3 (Dietary Interventions for Weight Loss)
More research is needed to inform future guidelines about
dietary interventions for weight loss.Because long-term dietary adherence is problematic in
weight management, to determine the best dietary
approach to sustain weight loss over the long term, studies
are needed that:
 Test the impact of tailoring choice of dietary in-
terventions on the individual’s ability to adhere in the
long term.
 Test pragmatic approaches to diet intervention de-
livery in free-living individuals for at least 2 years
duration.
 Evaluate the physiological and biological adaptations
to weight loss, so as to reﬁne methods of caloric
restriction during weight reduction and maintenance.4.4. CQ4 (Lifestyle Interventions for Weight Loss)
More research is needed to inform future guidelines
focusing on improvements in efﬁciency and efﬁcacy,
optimizing delivery and dissemination, and targeting spe-
cial populations. The research is needed in the following
areas:
 On-site (face-to-face), comprehensive, high-intensity
lifestyle interventions (14 or more contacts in ﬁrst
6months) represent the standard for behavioral weight
loss interventions. Further research can help improve
efﬁciency of these interventions with studies that:
 Evaluate optimal frequency (and duration) of
contact.
 Evaluate characteristics of those who lose less
weight in response to a standard, comprehensive
behavioral intervention, and develop alternative
approaches for their treatment.
 Evaluate effective methods of delivering lifestyle
interventions remotely (e.g., Internet, mobile
phone, text messaging, telephone, DVDs, or
some combination of these) to achieve and
maintain clinically meaningful weight loss.
 Because of changing demographics, there is a need
for further research to understand the most appro-
priate strategies and prescriptions for weight loss for
some key populations, including older adults and
racial/ethnic groups.
 Because the efﬁcacy of on-site (face-to-face),
comprehensive, high-intensity lifestyle intervention
has been established in academic settings, trans-
lational studies are needed that:
 Evaluate programs that can be delivered in com-
munity, work-site, and other settings (including
commercial programs).
 Determine the personal characteristics, skills, and
training required of a lifestyle interventionist.
 Identify the optimal role for PCPs to play in the
management of obesity by lifestyle modiﬁcation.
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effectiveness and associated costs of delivering
interventions on site (face-to-face), remotely, or by
a combination of approaches (i.e., hybrid delivery).
 Because maintenance of lost weight over the long
term has been challenging, studies are needed that:
 Evaluate strategies to promote additional weight
loss beyond the ﬁrst 6 months, the time at which
weight loss plateaus in most individuals.
 Evaluate novel methods of improving the main-
tenance of lost weight.
 Further study is needed on the effect of weight loss
treatment on healthcare utilization and cost.4.5. CQ5 (Surgical Procedures for Weight Loss)
More research is needed to inform future guidelines in the
following areas:
 Because bariatric surgery offers the potential for
prevention or remission of diabetes, better control of
cardiovascular risk factors, improvement in quality of
life and possibly decreased mortality, there is a need
for research to better characterize those patients who
are most likely to beneﬁt from and least likely to
suffer adverse consequences of bariatric surgical
procedures.
 Large and well-designed experimental, quasi-
experimental, and observational studies with long-
term follow-up are needed to determine whether
the risks and beneﬁts of bariatric surgery are sus-
tained over time. Studies are needed that:
 Evaluate which surgical procedures are best
applied to different populations, on the basis of
factors such as presence and duration of comorbid
conditions, age, sex, race/ethnicity, degree and
duration of obesity, underlying genetic etiologies,
and psychosocial or behavioral characteristics.
 Evaluate the implementation of bariatric surgery
in nonacademic settings, which may be more
reﬂective of real-world clinical practice.Presidents and Staff
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